Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07033481 · ClinicalTrials.gov registry record · Phase 2
Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia
A Phase 2 study of Nonfluent Variant Primary Progressive Aphasia (nfvPPA), sponsored by EIP Pharma.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 3
- Study locations
NCT07033481: Recruiting Phase 2 study of Nonfluent Variant Primary Progressive Aphasia (nfvPPA), sponsored by EIP Pharma.
NCT07033481 is a Phase 2 study of Nonfluent Variant Primary Progressive Aphasia (nfvPPA) that is actively recruiting participants, run by EIP Pharma. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07033481, a Phase 2 study of Nonfluent Variant Primary Progressive Aphasia (nfvPPA), is actively recruiting participants, sponsored by EIP Pharma.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this exploratory study is to evaluate the effect of neflamapimod in participants with nonfluent variant primary progressive aphasia (nfvPPA). We aim to evaluate the safety, pharmacokinetics and clinical effects of neflamapimod of participants with nfvPPA.
Primary Outcome
The number and proportion of participants experiencing adverse events (AEs) and serious adverse events (SAEs) during the study period, categorized by severity and relationship to the study intervention.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Neflamapimod
Study Locations (3)
Minnesota
- Mayo Clinic - Rochester
Ohio
- The Ohio State University - Columbus
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-08 |
| Est. Completion | 2026-10 |
| Phase | Phase 2 |
What NCT07033481 shows while recruiting
NCT07033481 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Nonfluent Variant Primary Progressive Aphasia (nfvPPA) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07033481 reports a single indexed study location in Minnesota, Ohio, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07033481 about?
NCT07033481 is a clinical study titled "Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia". The goal of this exploratory study is to evaluate the effect of neflamapimod in participants with nonfluent variant primary progressive aphasia (nfvPPA). We aim to evaluate the safety, pharmacokinetics and clinical effects of neflamapimod of participants with nfvPPA.
What is the current status of trial NCT07033481?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2025-08. Estimated completion is 2026-10.
What conditions does trial NCT07033481 study?
This clinical trial studies the following conditions: Nonfluent Variant Primary Progressive Aphasia (nfvPPA).
What interventions are being tested in trial NCT07033481?
The interventions under investigation include: Placebo (DRUG), Neflamapimod (DRUG).
Who is sponsoring clinical trial NCT07033481?
This trial is sponsored by EIP Pharma, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07033481 being conducted?
This trial has 3 study locations across Minnesota, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nonfluent Variant Primary Progressive Aphasia (nfvPPA)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07033481's enrollment target sits among peer trials
20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia